Articles tagged with Drug Studies
Researchers used human-induced pluripotent stem cell-derived kidney organoids to model nephronophthisis, revealing the Hippo signaling pathway's role in fibrosis. Inhibiting this pathway with drugs like verteporfin shows promise as a treatment option.
Researchers found high-engagement social media posts lack essential risk information and promotional elements, potentially eroding patient decision-making. The study highlights the need for fair balance in online advertising to maintain informed consent.
Researchers found olezarsen significantly reduced acute pancreatitis incidence by 85% in patients with severely elevated triglyceride levels. The drug also lowered triglyceride levels below 500mg/dL in over 85% of participants.
In a clinical trial of 12,257 patients at high risk, investigators found that adding the drug evolocumab to a patient’s treatment reduced the risk of a first heart attack, first stroke, or coronary heart disease death by 25%. The study also showed a 36% reduction in heart attacks and a nominally lower rate of death in the evolocumab arm.
The DEFEND study aims to assess whether virtual exercise sessions can be successfully delivered to patients with cancer receiving chemotherapy. Researchers will evaluate the impact on physical function, fatigue, and disability.
Three new Cochrane reviews found GLP-1 drugs result in clinically meaningful weight loss, but evidence on longer-term outcomes and side effects is limited. The wider use of these drugs should consider social and commercial determinants to avoid deepening existing health inequities.
The FDA has approved elinzanetant for treating hot flashes and night sweats in postmenopausal women. The drug significantly reduces the frequency and severity of symptoms while improving sleep quality and quality of life.
A new Alliance trial is exploring the effectiveness of a combination of targeted therapy and immunotherapy for patients with advanced adrenocortical carcinoma, a rare and aggressive cancer. The study aims to improve disease control and quality of life for patients with limited treatment options.
The termination of thousands of federal grants has raised ethical concerns about clinical trial closures, particularly among children and adolescents. Researchers argue that sudden stops can break trust and harm participants, violating long-standing principles.
A new clinical trial found that adding a PSMA-targeting agent to stereotactic radiation therapy doubled progression-free survival in patients with limited metastatic prostate cancer. The study also showed that the treatment delayed hormone therapy by 24 months and improved local control.
Researchers have designed a novel quintuple agonist combining GLP-1R, GIPR, and PPAR agonism to treat obesity and type 2 diabetes. The molecule, lanifibranor, shows potent effects in reducing body weight and improving hyperglycaemia in mice with obesity and insulin resistance.
Researchers are testing whether low-concentrate atropine drops can delay the onset of myopia in children. The study aims to reduce the risk of sight-threatening complications later in life by decreasing how nearsighted someone becomes.
A large international clinical trial found that elinzanetant significantly reduces hot flashes and night sweats in postmenopausal women by over 73%. The drug also shows secondary benefits such as improved quality of life and reduced sleep disturbances, with no harmful effects on the liver or bone density.
A daily pill of baricitinib, a Janus kinase inhibitor, preserves insulin-producing beta cell function and slows type 1 diabetes progression in people recently diagnosed with the condition. The treatment's therapeutic effect is lost when it's stopped, justifying its testing in earlier stages to prevent or delay clinical diagnosis.
The Ver-A-T1D trial suggests that verapamil could preserve beta-cell function in adults with newly diagnosed type 1 diabetes. The study demonstrated encouraging trends towards beta-cell preservation and well-established safety profile, but narrowly missed statistical significance.
A randomized clinical trial shows that low-dose aspirin reduces the risk of recurrence by 55% in patients with colon and rectal cancer harboring a specific genetic mutation. Aspirin's anti-inflammatory and anti-tumor effects may be responsible for its therapeutic benefits.
A phase 3 trial of once-daily orforglipron found substantial weight loss in people with obesity but not type 2 diabetes. The medication improved cardiometabolic levels and was associated with significant reductions in body weight, waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol.
A recent study found that two-thirds of clinical trial participants experienced complete remission from major depressive disorder five years after psilocybin-assisted therapy. The treatment also showed significant and large reduction in depression symptoms, with many participants reporting improved well-being measures.
A new study from Mizzou's College of Veterinary Medicine analyzed the effects of radioactive iodine therapy on thyroid cancer in dogs. The research found that tailoring the dose of radiation more precisely for each dog could improve outcomes and potentially lead to more targeted care.
A comprehensive registry study in Sweden found that healthy, full-term babies under three months old are at risk of severe illness from RSV. The study highlights several risk factors, including birth weight and sibling age, which increase the risk of needing intensive care or dying.
Researchers found that individuals from African American, Hispanic and Asian groups were less likely to have elevated amyloid in the brain based on blood levels of p-tau217. This finding suggests that these groups may have a lower prevalence of amyloid and are not at sufficient risk to qualify for amyloid-lowering trials.
Ibezapolstat, a new antibiotic, has been shown to be effective in treating Clostridioides difficile (C. diff) infections with high rates of sustained clinical cures. The study found that ibezapolstat killed harmful bacteria without harming the good bacteria in the gut, which helps prevent recurrent C. diff infections.
A single dose of MM120 (lysergide) produced a dose-dependent reduction in anxiety in participants with moderate to severe generalized anxiety disorder. The study supports the efficacy of MM120 and informs dose selection for phase 3 pivotal trials.
Semaglutide significantly reduces cocaine-seeking behavior in rats by 26%, with a 62% drop in seeking after abstinence. This finding suggests semaglutide's potential as a treatment for human cocaine dependency, currently lacking effective pharmacological options.
A clinical trial led by Professor Robert Bals found that azelastine nasal spray significantly reduced the risk of SARS-CoV-2 infection by 66%. The treatment group showed fewer symptomatic infections and lower respiratory rates compared to the placebo group.
A new study published in The New England Journal of Medicine and the European Heart Journal finds that beta blockers, commonly prescribed after a heart attack, provide no clinical benefit for patients with preserved heart function. Women treated with beta blockers had a higher risk of death, heart attack, or hospitalization for heart f...
A clinical trial led by Tohoku University has found that lubiprostone can prevent the decline of renal function in patients with chronic kidney disease. The study evaluated the effects of lubiprostone on kidney function and found that it improves mitochondrial function, which exerts a renoprotective effect.
A new class of targeted therapy showed promise in treating head and neck squamous cell carcinoma (HNSCC) in pet cats, with 35% of patients experiencing controlled disease. The drug, which targets the transcription factor STAT3, also raised levels of PD-1, a protein associated with an immune response to cancer.
Research from the University of South Australia finds that ibuprofen and paracetamol drive antibiotic resistance when used individually, but amplifying it when combined. The study also reveals that common bacteria like E. coli become highly resistant to antibiotics and multiple other medications.
A new RP-HPLC method has been developed and validated for the analysis of orlistat, a widely used anti-obesity drug. The method ensures accurate quantification and is fully compliant with International Council for Harmonisation (ICH) guidelines, reducing solvent use and analysis time.
A new imaging approach allows researchers to visualize how dual-acting diabetes and obesity drugs like tirzepatide interact with cells in the pancreas and brain. The tool, called daLUXendins, provides insight into the metabolic effects triggered by these drugs, which stimulate both GLP-1R and GIPR receptors.
Researchers from Australia and China have found nine high-priority pathogens in aircraft lavatory wastewater, including some resistant to multiple drugs. The study suggests that monitoring aircraft wastewater could provide an early warning system for the spread of antimicrobial-resistant superbugs.
Researchers have found a way to rearrange atoms in a new generation of malaria drugs to make them more soluble, maintaining their effectiveness against drug-resistant parasites. This breakthrough could lead to an effective successor to artemisinin-based combination therapy.
Researchers developed a deep learning model to predict ADRs using molecular structures, achieving high accuracy in detecting rare effects and minimal risk for novel molecules. The model demonstrated potential as a decision-support tool in early-phase drug discovery and regulatory safety monitoring.
A recent University of Michigan study found that nonmedical use of prescription ADHD drugs among adolescents has dropped from 10% in 2005 to 6% in 2023. Lifetime medical use also increased slightly during the same period, but overall trends suggest a decrease in misusing these prescriptions.
Researchers have developed a groundbreaking method to observe lysosomes in live suspended cells—quantitatively, in 3D, and without the use of chemical labels. The technology uses holographic tomography in flow cytometry configuration (HTFC) to identify morphological and spatial lysosomal changes in models of lysosomal storage diseases.
Researchers Dr. Sharday Mosurinjohn and Dr. Richard Ascough critique the 'psychedelic mysteries hypothesis' in a new article, arguing that it relies on circumstantial evidence rather than solid historical scholarship. They advocate for responsible curiosity and a focus on living traditions to unlock psychedelic wisdom.
Researchers at Kyoto University have discovered a novel analgesic called ADRIANA, which targets the α2B-adrenoceptor and exerts its effect without causing cardiovascular instability. The compound has shown highly promising results in non-clinical studies and early clinical trials.
A new treatment for corneal scarring is being developed by University of Houston optometry researcher Tarsis G. Ferreira. The treatment uses a natural protein called decorin to block scarring and unwanted blood vessel growth, offering hope for people with injured corneas.
Researchers from FAU's Schmidt College of Medicine recommend using high-potency statins as the primary pharmacologic approach in treating and preventing cardiovascular disease. Lifestyle changes, such as regular physical activity and a healthy diet, are also crucial in reducing cardiovascular risk.
Researchers used an AI model to reassess a completed clinical trial for an Alzheimer's disease drug, finding it slowed cognitive decline by 46% in early-stage patients. The AI model predicts patient progression and allows for more precise selection of trial participants, potentially reducing the cost of developing new medicines.
Dr. Mirko Manchia's groundbreaking research identifies genetic markers predicting treatment response in bipolar patients, enabling precision medicine approaches to transform psychiatric care. He envisions a future where genetic testing becomes routine in psychiatric care.
Researchers have identified a hidden molecular mechanism involving two proteins that allows tumors to resist treatment. A new gelatin-based nanoparticle has been developed to shut down both proteins simultaneously, showing promising results in early studies with mice.
Clinical trials show sutezolid and delpazolid are safer alternatives to linezolid for treating drug-resistant TB, with no cases of nerve damage or blood toxicity reported. The findings suggest these drugs could replace linezolid in treatment regimens.
A new study highlights major hurdles for multinational clinical trials in Europe, including differences in timelines and processing times between countries. Researchers found that the UK made significant gains in efficiency during the pandemic, while non-UK countries lagged behind.
A team of researchers proposes a novel adaptive platform trial fund to accelerate ALS drug development. The study outlines a financing model that merges efficiencies with an innovative royalty-based investment structure, drawing on data from the HEALEY ALS Platform Trial. This new approach could transform how diseases like ALS are addr...
Researchers have discovered an oral drug called MA-5 that can improve both heart and muscle problems in patients with Barth syndrome, a rare genetic disorder. The drug boosts cellular energy production by up to 50% and protects cells from oxidative stress-induced death, addressing the underlying cause of the disease.
UVA Health received two anonymous $25 million estate gifts to support the Paul and Diane Manning Institute of Biotechnology. The institute will develop new treatments for hard-to-treat diseases with a state-of-the-art biomedical research facility expected to drive economic growth in Central Virginia.
A new study from Karolinska Institutet found that biological drugs used to treat severe asthma do not completely eradicate inflammatory cells. Researchers discovered an increase in blood levels of these cells during treatment, which could explain why inflammation often returns when treatment is tapered or discontinued. The study aims t...
A common medication used for autoimmune diseases has been found to be effective in treating giant cell arteritis, with nearly half of patients achieving sustained remission. The treatment reduces dependence on glucocorticoids, a common but side-effect-ridden option.
The experimental drug SANA has been shown to prevent fat accumulation, treat existing obesity, and reverse associated metabolic disorders. In animal tests, it activated thermogenesis through an unconventional mechanism, targeting adipose tissue cells to produce heat without involving the UCP1 protein.
Researchers at University of Cologne have discovered a previously unknown mechanism that explains why many patients with aggressive B-cell lymphoma don't respond to CAR-T cell therapy. Combining this innovative treatment with CSF1R inhibitors improves its effectiveness, according to the study published in Cancer Cell.
Researchers discover iguratimod, a rheumatoid arthritis drug, effectively treats excessive COVID-19 inflammation in mice by maintaining antiviral immune responses. The study provides hope for patients with severe COVID-19-related cytokine storms.
Researchers have discovered that nicotinamide riboside supplementation significantly improves NAD+ levels, reducing arterial stiffness, skin ulcer area, and kidney dysfunction. This breakthrough offers new hope for patients with Werner syndrome who lack effective treatment options.
Long-term data from the Phase 1/2 study of zigakibart demonstrate sustained proteinuria remission, stable kidney function, and a reassuring safety profile in patients with IgA nephropathy. The treatment also led to reductions in serum immunoglobulins, consistent with APRIL pathway inhibition.
The annual Alzheimer's disease drug development pipeline report, led by Dr. Jeffrey Cummings, highlights an increase in active clinical trials and promising drugs, offering reason for optimism. The report assesses 138 drugs currently being studied and notes the growing importance of biomarkers in clinical trials.
The S2302 Pragmatica-Lung trial found that the investigational combination of ramucirumab and pembrolizumab did not extend overall survival compared to standard-of-care treatments. The study enrolled a highly representative population of patients, establishing it as a paradigm-shifting model for large randomized studies.
A WVU microbiology student has discovered a new species of fungus, Periglandula clandestina, that produces effects similar to the semisynthetic drug LSD. The fungus is highly efficient at making ergot alkaloids, which can be used therapeutically to treat conditions like depression and addiction.
A Kennedy Krieger researcher's work on a promising oral drug, leriglitazone, has shown it can slow the progression of cerebral adrenoleukodystrophy (cALD) in all 11 trial participants. Nearly half of boys treated with the medication appeared to halt disease progression entirely.
DB-1310, a HER3-targeted antibody-drug conjugate, has shown real potential as a new treatment option for patients with advanced solid tumors that have progressed after standard therapies. In an international clinical trial, DB-1310 demonstrated significant tumor shrinkage and delayed cancer growth in 44% of EGFR-mutant NSCLC patients.